Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara; Carson Norwood; Katharine Floyd; Lilin Lai; Meredith E. Davis-Gardner; William H. Hudson; Grace Mantus; Lindsay E. Nyhoff; Max W. Adelman; Rebecca Fineman; Shivan Patel; Rebecca Byram; Dumingu Nipuni Gomes; Garett Michael; Hayatu Abdullahi; Nour Beydoun; Bernadine Panganiban; Nina McNair; Kieffer Hellmeister; Jamila Pitts; Joy Winters; Jennifer Kleinhenz; Jacob Usher; James B. O'Keefe; Anne Piantadosi; Jesse J. Waggoner; Ahmed Babiker; David S. Stephens; Evan J. Anderson; Srilatha Edupuganti; Nadine Rouphael; Rafi Ahmed; Jens Wrammert; Mehul S. Suthar

doi:10.1016/j.chom.2021.03.009

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Venkata Viswanadh Edara, Carson Norwood, Katharine Floyd, Lilin Lai, Meredith E. Davis-Gardner, William H. Hudson, Grace Mantus, Lindsay E. Nyhoff, Max W. Adelman, Rebecca Fineman, Shivan Patel, Rebecca Byram, Dumingu Nipuni Gomes, Garett Michael, Hayatu Abdullahi, Nour Beydoun, Bernadine Panganiban, Nina McNair, Kieffer Hellmeister, Jamila PittsJoy Winters, Jennifer Kleinhenz, Jacob Usher, James B. O'Keefe, Anne Piantadosi, Jesse J. Waggoner, Ahmed Babiker, David S. Stephens, Evan J. Anderson, Srilatha Edupuganti, Nadine Rouphael, Rafi Ahmed, Jens Wrammert, Mehul S. Suthar

Research output: Contribution to journal › Article › peer-review

151 Scopus citations

Abstract

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

Original language	English (US)
Pages (from-to)	516-521.e3
Journal	Cell Host and Microbe
Volume	29
Issue number	4
DOIs	https://doi.org/10.1016/j.chom.2021.03.009
State	Published - Apr 14 2021

Keywords

SARS-CoV-2
emerging variants
humoral immunity
receptor-binding domain
vaccine
viral neutralization

ASJC Scopus subject areas

Parasitology
Microbiology
Virology

Access to Document

10.1016/j.chom.2021.03.009

Cite this

Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., Patel, S., Byram, R., Gomes, D. N., Michael, G., Abdullahi, H., Beydoun, N., Panganiban, B., McNair, N., Hellmeister, K., ... Suthar, M. S. (2021). Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host and Microbe, 29(4), 516-521.e3. https://doi.org/10.1016/j.chom.2021.03.009

Edara, VV, Norwood, C, Floyd, K, Lai, L, Davis-Gardner, ME, Hudson, WH, Mantus, G, Nyhoff, LE, Adelman, MW, Fineman, R, Patel, S, Byram, R, Gomes, DN, Michael, G, Abdullahi, H, Beydoun, N, Panganiban, B, McNair, N, Hellmeister, K, Pitts, J, Winters, J, Kleinhenz, J, Usher, J, O'Keefe, JB, Piantadosi, A, Waggoner, JJ, Babiker, A, Stephens, DS, Anderson, EJ, Edupuganti, S, Rouphael, N, Ahmed, R, Wrammert, J & Suthar, MS 2021, 'Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant', Cell Host and Microbe, vol. 29, no. 4, pp. 516-521.e3. https://doi.org/10.1016/j.chom.2021.03.009

@article{b99fa91ae51e4fd09761dd50fc9fae65,

title = "Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant",

abstract = "The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.",

keywords = "SARS-CoV-2, emerging variants, humoral immunity, receptor-binding domain, vaccine, viral neutralization",

author = "Edara, {Venkata Viswanadh} and Carson Norwood and Katharine Floyd and Lilin Lai and Davis-Gardner, {Meredith E.} and Hudson, {William H.} and Grace Mantus and Nyhoff, {Lindsay E.} and Adelman, {Max W.} and Rebecca Fineman and Shivan Patel and Rebecca Byram and Gomes, {Dumingu Nipuni} and Garett Michael and Hayatu Abdullahi and Nour Beydoun and Bernadine Panganiban and Nina McNair and Kieffer Hellmeister and Jamila Pitts and Joy Winters and Jennifer Kleinhenz and Jacob Usher and O'Keefe, {James B.} and Anne Piantadosi and Waggoner, {Jesse J.} and Ahmed Babiker and Stephens, {David S.} and Anderson, {Evan J.} and Srilatha Edupuganti and Nadine Rouphael and Rafi Ahmed and Jens Wrammert and Suthar, {Mehul S.}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = apr,

day = "14",

doi = "10.1016/j.chom.2021.03.009",

language = "English (US)",

volume = "29",

pages = "516--521.e3",

journal = "Cell Host and Microbe",

issn = "1931-3128",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

AU - Edara, Venkata Viswanadh

AU - Norwood, Carson

AU - Floyd, Katharine

AU - Lai, Lilin

AU - Davis-Gardner, Meredith E.

AU - Hudson, William H.

AU - Mantus, Grace

AU - Nyhoff, Lindsay E.

AU - Adelman, Max W.

AU - Fineman, Rebecca

AU - Patel, Shivan

AU - Byram, Rebecca

AU - Gomes, Dumingu Nipuni

AU - Michael, Garett

AU - Abdullahi, Hayatu

AU - Beydoun, Nour

AU - Panganiban, Bernadine

AU - McNair, Nina

AU - Hellmeister, Kieffer

AU - Pitts, Jamila

AU - Winters, Joy

AU - Kleinhenz, Jennifer

AU - Usher, Jacob

AU - O'Keefe, James B.

AU - Piantadosi, Anne

AU - Waggoner, Jesse J.

AU - Babiker, Ahmed

AU - Stephens, David S.

AU - Anderson, Evan J.

AU - Edupuganti, Srilatha

AU - Rouphael, Nadine

AU - Ahmed, Rafi

AU - Wrammert, Jens

AU - Suthar, Mehul S.

PY - 2021/4/14

Y1 - 2021/4/14

N2 - The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

AB - The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.

KW - SARS-CoV-2

KW - emerging variants

KW - humoral immunity

KW - receptor-binding domain

KW - vaccine

KW - viral neutralization

UR - http://www.scopus.com/inward/record.url?scp=85103563984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103563984&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2021.03.009

DO - 10.1016/j.chom.2021.03.009

M3 - Article

C2 - 33798491

AN - SCOPUS:85103563984

SN - 1931-3128

VL - 29

SP - 516-521.e3

JO - Cell Host and Microbe

JF - Cell Host and Microbe

IS - 4

ER -

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this